Gilead to acquire Arcellx for $7.8 billion

SelfRugger · 2026-02-28T09:13:20+00:00

Gilead Sciences plans to acquire Arcellx for $7.8 billion, boosting Arcellx's shares by 77.8% to $113.99. The deal includes $115 per share in cash and a $5 contingent value right, representing a significant premium.

SelfRugger

2026-02-28 09:13:20

Abstract generation in progress

Gilead to acquire Arcellx for $7.8 billion

Reuters

Mon, February 23, 2026 at 8:15 PM GMT+9

In this article:

GILD

+0.19%

ACLX

-3.64%

Feb 23 (Reuters) - Gilead Sciences said ‌on Monday it ‌will buy cancer therapy developer Arcellx for an implied equity value of $7.8 ‌billion, ⁠sending shares of Arcellx climbing ⁠77.8% to $113.99 in premarket trading.

NasdaqGS - Delayed Quote • USD

(ACLX)

Follow    



  View Quote Details

64.11 -2.42 (-3.64%)

At close: February 20 at 4:00:01 PM EST

Advanced Chart

Gilead will pay $115 per share in ‌cash at the deal’s closing and one contingent value right of $5 per ‌share, which is a premium of ‌87% to the stock’s last close.

(Reporting by Christy Santhosh in ‌Bengaluru; Editing by Leroy Leo and Pooja Desai)

Sign up for the Yahoo Finance Morning Brief

    By subscribing, you are agreeing to Yahoo's 
            
                Terms
            
         and 
            
                Privacy Policy
            
         







 Subscribe

Terms and Privacy Policy

Privacy Dashboard

More Info

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.